Form 4: RenovoRx CEO Shaun Bagai Granted 946,107 Stock Options

RenovoRx, Inc. CEO Shaun Bagai has been granted nearly 1 million stock options with a four-year vesting schedule starting January 2026.

Summary

• CEO Shaun Bagai was granted 946,107 stock options on April 3, 2026.
• The options have an exercise price of 0.98 per share.
• The grant consists of 111,621 incentive stock options and 834,486 non-qualified stock options.
• Vesting occurs over 48 months at a rate of 1/48 per month, retroactively starting from January 1, 2026.
• The options will become fully vested on January 1, 2030, and expire on April 3, 2036.
• Exercisability is contingent upon the company having an effective registration statement covering the underlying shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive signal of executive commitment and alignment, though it carries standard dilutive implications for shareholders.

Positives

• Strong alignment of interests between the Chief Executive Officer and shareholders through equity-based compensation.
• Long-term vesting schedule of four years encourages executive retention and long-term strategic planning.
• The exercise price of 0.98 sets a clear baseline for management to drive share price appreciation.

Negatives

• Potential future dilution of approximately 946,107 shares for existing shareholders upon exercise.
• The options cannot be exercised until a registration statement is effective, which introduces a regulatory dependency.

Risks

• Dilution risk as the total number of outstanding shares will increase if these options are exercised.
• The value of the compensation is entirely dependent on the market price of the stock remaining above 0.98.
• Regulatory risk regarding the maintenance of an effective registration statement required for the options to be exercisable.

Future Outlook

The grant indicates a commitment to executive stability through 2030. The company must ensure it meets regulatory requirements for a registration statement to allow these options to be converted into tradable common stock.

Management Comments

• The grant was approved by the Compensation Committee of the Board of Directors.

Industry Context

StockSavvy.ai notes that significant equity grants for CEOs in the biotechnology and medical device sectors are standard practice to align management incentives with long-term clinical and regulatory milestones.

Comparison to Industry Standards

• A four-year vesting period is a standard benchmark for executive equity compensation in U.S. public companies.
• The use of both Incentive Stock Options (ISOs) and Non-Qualified Stock Options (NQSOs) is a common strategy to balance tax benefits for the executive and the company.
• Monthly vesting without an initial one-year cliff is slightly more favorable to the executive than many standard startup or mid-cap biotech equity structures.

Corporate Governance

Related Party Transactions

• Grant of stock options to Shaun Bagai, who serves as both the Chief Executive Officer and a Director of the company.

Stakeholder Impact

• Shareholders face potential dilution of nearly 1 million shares over the next four years.
• The CEO is incentivized to increase the company's market valuation above the 0.98 strike price to realize value from the grant.

Next Steps

• Ensure an effective registration statement is in place to allow for future option exercises.
• Continue monthly vesting of the grant through the 2030 expiration of the vesting term.

Key Dates

Recommendation

The filing represents a standard executive compensation event. While it demonstrates management alignment, it does not provide new fundamental data regarding clinical progress or financial runway that would necessitate a change in investment rating.

Keywords

RenovoRx, RNXT, Shaun Bagai, Stock Options, Executive Compensation, Insider Transaction, Form 4, CEO Grant